Bank of America Securities Keeps Their Buy Rating on Lyell Immunopharma (LYEL)
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‐stage T-cell reprogramming company advancing a diverse pipeline of cell therapies fo
Express News | HC Wainwright & Co. Reiterates Buy on Lyell Immunopharma, Maintains $6 Price Target
Lyell Immunopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 136.22% HC Wainwright & Co. → $6 Reiterates Buy → Buy 02/29/2024 136.22% HC Wainwright & Co. $8
Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows
Lyell Immunopharma (LYEL) shares were up nearly 4% in recent trading Monday, after Q1 net loss narrowed. The company reported Q1 net loss of $0.24 per diluted share, narrowing from a loss of $0.27 a y
Lyell Immunopharma | 10-Q: Quarterly report
Express News | Lyell Immunopharma- Cash, Cash Equivalents,Marketable Securities Balances to Be Sufficient to Meet Working Capital & Capex Needs Into 2027
Express News | Lyell Immunopharma Inc - on Track to Report Initial Clinical Data From Phase 1 Trial of Lyl845 in Second Half of 2024
Express News | Lyell Immunopharma Inc - Expect to Share Initial Clinical and Translational Data From Phase 1 Trial of Lyl797 This Quarter
Express News | Lyell Immunopharma Inc - Ind for Second Generation Ror1-Targeted Car T-Cell Product Candidate on Track for Submission This Quarter
Express News | Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
Express News | Lyell Immunopharma Q1 Net Income USD -60.667 Million
Press Release: Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical--stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors today reported financial results and business highlights for the first quarter ended March 31, 2024.
Lyell Immunopharma Cash, Cash Equivalents and Marketable Securities of $526.3M as of March 31 >LYEL
Lyell Immunopharma Cash, Cash Equivalents and Marketable Securities of $526.3M as of March 31 >LYEL
Lyell Immunopharma 1Q Rev $3,000 >LYEL
Lyell Immunopharma 1Q Rev $3,000 >LYEL
Lyell Immunopharma Sees Insider Stock Selling
Viewing insider transactions for Lyell Immunopharma, Inc.'s (NASDAQ:LYEL ) over the last year, we see that insiders were net sellers. This means that a larger number of shares were sold by insiders in
Argan Reports Upbeat Earnings, Joins Coupang And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Dow Jones index falling over 250 points on Friday. Shares of Argan, Inc. (NYSE:AGX) rose sharply during Friday's session as the company reported better-than-expected
CERS, GL and ATHE Are Among Pre Market Gainers
GLYC, APLD and AUTL Are Among After Hour Movers
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersOntrak (NASDAQ:OTRK) shares increased by 18.7% to $0.45 during Thursday's after-market session. The company's market cap stands at $18.9 million. Ocuphire Pharma (NASDAQ:OCUP) stock rose 7.82%